CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.

Florian FrankHanno UlmerVictoria SidoroffGregor Broessner

Published in: Cephalalgia : an international journal of headache (2021)

Topiramate, botulinum toxin type A and monoclonal antibodies showed higher odds ratios in achieving a 50% response rate compared to placebo. Topiramate numerically demonstrated the greatest effect size but also the highest drop-out rate.

Keyphrases

botulinum toxin
randomized controlled trial
clinical trial
drug induced
open label